Time To Intensify: Taking mAb Manufacturing To The Next Level

By Gerben Zijlstra, Jean-Marc Cappia, Sartorius

Demand for monoclonal antibodies (mAbs) is growing by over 10% annually to treat a wide range of conditions, including cancer, infectious diseases, and autoimmune disorders. As the mAb industry works to meet global healthcare needs, it is also facing pressure to speed up drug development, lower costs, and improve manufacturing efficiency and sustainability.

This white paper explores how an end-to-end process intensification (PI) strategy can transform your mAb manufacturing. Discover practical, scalable approaches to intensify upstream and downstream processes, and learn about the analytical strategies that support them. We'll share real-world results, technology guidance, and expert insights to help you implement PI effectively.

Learn to:

• Improve productivity, flexibility, and cost-efficiency with PI.
• Understand upstream and downstream intensification technologies.
• De-risk your PI implementation with integrated analytics and automation.